Investors

2023

For the purposes of the Financial Conduct Authority's (FCA) Disclosure and Transparency Rules, the issued ordinary share capital of the Company comprises 78,543,318 ordinary shares of 2p each ('Ordinary Shares').

The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares carrying voting rights in the Company is 78,543,318. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

The Company has been made aware that as a result of a typographical error on an application for admission in January 2015 sixty ordinary shares had not been admitted to trading on AIM. Application has now been made for these sixty shares to be admitted to trading on AIM which is expected to occur on or around 4 August 2017. There is no change to the issued share capital as a result of this application, which was correctly notified at the time.

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2022

For the purposes of the Financial Conduct Authority's (FCA) Disclosure and Transparency Rules, the issued ordinary share capital of the Company comprises 78,543,318 ordinary shares of 2p each ('Ordinary Shares').

The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares carrying voting rights in the Company is 78,543,318. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

The Company has been made aware that as a result of a typographical error on an application for admission in January 2015 sixty ordinary shares had not been admitted to trading on AIM. Application has now been made for these sixty shares to be admitted to trading on AIM which is expected to occur on or around 4 August 2017. There is no change to the issued share capital as a result of this application, which was correctly notified at the time.

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2021

For the purposes of the Financial Conduct Authority's (FCA) Disclosure and Transparency Rules, the issued ordinary share capital of the Company comprises 78,543,318 ordinary shares of 2p each ('Ordinary Shares').

The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares carrying voting rights in the Company is 78,543,318. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

The Company has been made aware that as a result of a typographical error on an application for admission in January 2015 sixty ordinary shares had not been admitted to trading on AIM. Application has now been made for these sixty shares to be admitted to trading on AIM which is expected to occur on or around 4 August 2017. There is no change to the issued share capital as a result of this application, which was correctly notified at the time.

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2020

For the purposes of the Financial Conduct Authority's (FCA) Disclosure and Transparency Rules, the issued ordinary share capital of the Company comprises 78,543,318 ordinary shares of 2p each ('Ordinary Shares').

The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares carrying voting rights in the Company is 78,543,318. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

The Company has been made aware that as a result of a typographical error on an application for admission in January 2015 sixty ordinary shares had not been admitted to trading on AIM. Application has now been made for these sixty shares to be admitted to trading on AIM which is expected to occur on or around 4 August 2017. There is no change to the issued share capital as a result of this application, which was correctly notified at the time.

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2019

For the purposes of the Financial Conduct Authority's (FCA) Disclosure and Transparency Rules, the issued ordinary share capital of the Company comprises 78,543,318 ordinary shares of 2p each ('Ordinary Shares').

The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares carrying voting rights in the Company is 78,543,318. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

The Company has been made aware that as a result of a typographical error on an application for admission in January 2015 sixty ordinary shares had not been admitted to trading on AIM. Application has now been made for these sixty shares to be admitted to trading on AIM which is expected to occur on or around 4 August 2017. There is no change to the issued share capital as a result of this application, which was correctly notified at the time.

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2018

For the purposes of the Financial Conduct Authority's (FCA) Disclosure and Transparency Rules, the issued ordinary share capital of the Company comprises 78,543,318 ordinary shares of 2p each ('Ordinary Shares').

The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of Ordinary Shares carrying voting rights in the Company is 78,543,318. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

The Company has been made aware that as a result of a typographical error on an application for admission in January 2015 sixty ordinary shares had not been admitted to trading on AIM. Application has now been made for these sixty shares to be admitted to trading on AIM which is expected to occur on or around 4 August 2017. There is no change to the issued share capital as a result of this application, which was correctly notified at the time.

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.